Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 244Melanoma 141Squamous Cell Carcinoma of Head and Neck 139Parkinson Disease 4, Autosomal Dominant Lewy Body 119Neoplasm Metastasis 104Triple Negative Breast Neoplasms 96Neoplasms 91Lung Neoplasms 91Breast Neoplasms 81Colorectal Neoplasms 70Carcinoma, Renal Cell 69Head and Neck Neoplasms 59Urinary Bladder Neoplasms 50Stomach Neoplasms 47Ovarian Neoplasms 46Endometrial Neoplasms 46Carcinoma, Transitional Cell 44Carcinoma, Hepatocellular 35Uterine Cervical Neoplasms 34Pancreatic Neoplasms 34Esophageal Neoplasms 27Prostatic Neoplasms 26Recurrence 25Carcinoma, Squamous Cell 25Carcinoma 25Sarcoma 24Brain Neoplasms 24Glioblastoma 23Hodgkin Disease 19Cholangiocarcinoma 19

Interventions

pembrolizumab 2Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumors × pembrolizumab × 1 year × Clear all
NCT07469774 2026-05-28

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Recruiting
111 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT05205109 2025-06-09

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Antengene Corporation

Phase 1 Recruiting
98 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡